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Abstract: Heart failure is a common and disabling condition with morbidity and mortality that 
increase dramatically with advancing age. Large observational studies, retrospective subgroup 
analyses and meta-analyses of clinical trials in systolic heart failure, and recently published 
randomized studies have provided data supporting the use of beta-blockers as a baseline therapy 
in heart failure in the elderly. Despite the available evidence about beta-blockers, this therapy is 
still less frequently used in elderly compared to younger patients. Nebivolol is a third-generation 
cardioselective beta-blocker with L-arginine/nitric oxide-induced   vasodilatory properties, approved 
in Europe and several other countries for the treatment of essential hypertension, and in Europe for 
the   treatment of stable, mild, or moderate chronic heart failure, in addition to standard therapies 
in elderly patients aged 70 years old or older. The effects of nebivolol on left ventricular   function 
in elderly patients with chronic heart failure (ENECA) and the study of effects of nebivolol 
  intervention on outcomes and rehospitalization in seniors with heart failure (SENIORS) have 
been specifically aimed to assess the efficacy of beta-blockade in elderly heart failure patients. 
The results of these two trials demonstrate that nebivolol is well tolerated and effective in reduc-
ing mortality and morbidity in older patients, and that the beneficial   clinical effect is present also 
in patients with mildly reduced ejection fraction. Moreover, nebivolol appears to be significantly 
cost-effective when prescribed in these patients. However, further targeted studies are needed to bet-
ter define the efficacy as well as safety profile in frail and older patients with comorbid diseases.
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Introduction
Heart failure shows an age-related increasing prevalence (affecting more than 10% of 
individuals over 75 years old), as a consequence of the aging of the population and the 
improvement in survival of patients with ischemic heart disease and hypertension.1–3 
As the mean age of patients in the community is about 76 years old,2–5 heart failure 
is considered a typical disorder of the elderly and is the most frequent reason for 
  hospital admissions among older people.5,6 The lifetime risk of developing heart fail-
ure is increasing and is currently estimated at 20%.7 Despite the recent advances in 
diagnosis and treatment, and although recent observations suggest an improvement 
of prognosis in the last decades,8 the mortality of older unselected patients remains 
significantly high, ranging from 26% to 38% at 1 year.4,6,9,10
Heart failure: age-related changes
Clinical assessments and the management of older patients are often more difficult 
than in younger ones and heterogeneity is the main clinical feature. Heterogeneity is Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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based on the dynamic definition of aging itself, as it is well 
known that biological age often does not equal demographic 
age. Epidemiological studies in geriatrics as well as in car-
diology settings have demonstrated that the essence of older 
  individuals is complex, with many clinical and nonclini-
cal factors determining different clinical presentation and 
prognosis.11,12 At advanced age, the cardiovascular status 
and, as a consequence global health, is the result of a com-
plex and dynamic interaction between three different areas: 
the changes related to “normal” aging of the cardiovascular 
system; the evolution of cardiovascular disease; and concomi-
tant comorbid conditions, social factors, and lifestyle.11–14 
Age-related changes throughout the cardiovascular system 
in combination with the high prevalence of cardiovascular 
diseases predispose older adults to the development of heart 
failure. These changes are mainly a consequence of increased 
left ventricular afterload secondary to increased aortic imped-
ance, and diminished sympathetic modulation.15
Clinical features that distinguish heart failure at advanced 
age from that occurring during middle age include an   increasing 
proportion of women and multiple etiologies with a shift from 
coronary heart disease to hypertension as the most common one, 
more severe clinical   manifestations,   comorbid diseases, and 
age-related conditions.13,14   Furthermore, as many as 30%–50% 
of elderly patients with heart failure may have normal systolic 
function.3 About 30%–40% of older patients with heart failure 
not only have hypertension, diabetes, renal failure, chronic 
obstructive pulmonary   disease (COPD), and anemia, but also 
cognitive impairment, incontinence, psychological problems, 
and limitations in activities of daily living.11,12
Overt heart failure in older persons is frequently associ-
ated with a worse prognosis. Data from the Italian Network 
on Congestive Heart Failure (CHF) registry suggest that 
age is an independent and powerful predictor of   mortality, 
with an increase in risk of about 3% per year of age,6 and 
a high mortality rate of older outpatients followed up by 
  cardiologists (up to 26% in the first year in patients .75 
years old).   Prognosis worsens with increasing New York 
Heart   Association (NYHA) functional class, but a variety 
of medical, functional, social, and psychocognitive factors 
may have significant effects on survival. Moreover, predictors 
of mortality vary by age and by the presence of preserved 
or reduced left ventricular ejection fraction (LVEF), and 
traditional predictors of mortality in patients with reduced 
LVEF may not apply to elderly patients with preserved LVEF. 
Finally, the importance of reducing   mortality in older patients 
may be questioned because of the reduced life expectancy 
and poor quality of life.
Pharmacologic treatment of elderly 
patients with heart failure
The quality of care of older heart failure patients is often far 
from satisfactory in clinical practice.5,6,11,16 Thus, the relative 
“under use” of evidence based treatments largely appears to 
depend on the higher complexity and the lack of definite evi-
dence on efficacy and safety of   nonpharmacological and phar-
macological treatments in the very elderly.12 Indeed, effective 
heart failure treatments such as   angiotensin-  converting 
enzyme (ACE) inhibitors, aldosterone antagonists, or beta-
blockers may be considered not indicated in the elderly 
because of the high prevalence of renal vascular disease, 
renal impairment, diabetes, COPD and other various reasons. 
Multidrug therapy is a common feature in older patients, with 
multiple cardiovascular and noncardiovascular medications 
used for several associated diseases. Drug interactions and 
adverse reactions are common when multiple medications 
are prescribed for elderly patients. Thus the older heart 
  failure population, which in fact comprises the majority of all 
patients, is in general less well studied, both experimentally 
and clinically, than younger populations.
Older patients are generally underrepresented in random-
ized clinical trials because only a few of them have addressed 
the impact of therapy in patients aged more than 70-years-old 
and virtually none included patients aged more than 
85-years-old. These observations are likely dependent on 
the eligibility criteria of clinical trials, in which only patients 
with a poor LVEF and without significant comorbidities are 
included, whereas preserved systolic function and comorbidi-
ties frequently characterize elderly people.
Thus, ACE-inhibitors, beta-blockers, angiotensin   receptor 
antagonists and aldosterone antagonists have shown a benefit 
in terms of mortality and rehospitalization only in patients 
with a mean age of 63 and reduced LVEF, and the evidence 
on the effects in elderly patients and those with preserved 
  systolic function are still limited. Recent guidelines pointed 
out the lack of adequate knowledge on heart failure   treatment 
in the elderly.17 It is evident that targeted clinical trials 
and rigorous observational studies are needed, aiming at 
  developing more effective treatments and favoring the imple-
mentation of specific guidelines into clinical practice.
Beta-blockers in older heart  
failure patients
During the past decade, randomized clinical trials have shown 
that carvedilol, bisoprolol and metoprolol significantly reduce 
mortality and hospital admissions, improve symptoms and 
slow the progression of the disease.18–20 However, these   trials Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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enrolled highly selected patients who were middle-aged, 
prevalently male, and with reduced systolic function. As a 
consequence, in clinical practice, older, complex patients 
have been undertreated with beta-blockers in comparison 
to younger ones, with doses approximately half the target 
of clinical trials. Indeed, the most frequent reasons for the 
limited use of beta-blockers and prescription of suboptimal 
doses are advanced age, concern about the potential risk of 
adverse events or worsening of symptoms, and the sizeable 
proportion of patients with preserved systolic function.
The subgroup analysis of randomized trials showed that 
beta-blockers reduce mortality also in older subgroups of 
patients (aged 60–80 years old) with systolic heart failure, 
and that the benefit was similar to that observed in younger 
ones (aged , 60 years).21,22 A meta-analysis of all-cause 
  mortality from five completed beta-blocker trials confirmed 
that elderly and nonelderly chronic heart failure patients 
derived considerable prognostic benefit from beta-blocker 
therapy without a statistically significant difference in 
  mortality reduction between the two groups. The relative 
risks of the elderly subgroup are reported in Figure 1.
Observational studies have assessed the effects of beta-
blockers in elderly patients from clinical practice, suggesting 
that beta-blockers may also be beneficial in these patients.23–25 
Sin and McAlister evaluated the associations between beta-
blocker use and outcomes in a population-based cohort of 
11,942 older (age # 65 years, mean 79 years old) patients 
between 1994 and 1999, with a propensity score adjusted 
analysis. Beta-blocker use was associated with substantial 
reductions in all-cause mortality (hazard ratio [HR] = 0.72; 
95% confidence interval [CI]: 0.65–0.80), mortality due to 
heart failure (HR = 0.65; 95% CI: 0.47–0.90), and hospital-
izations for heart failure (HR = 0.82; 95% CI: 0.74–0.92). 
These endpoints were less frequent in patients treated with 
beta-blockers than in untreated patients in all examined 
subgroups. All doses of beta-blockers were associated with 
  benefit, but there was a trend towards greater benefit in patients 
prescribed higher doses. This observational study confirmed 
that the benefits of beta-blockers seen in randomized trials 
extend to older patients and to those with conditions that would 
have led to their exclusion from the trials.
Recently, another observational study examined the 
associations between beta-blocker therapy and outcomes 
among elderly patients hospitalized for heart failure in the 
Organized Program to Initiate Lifesaving Treatment in Hos-
pitalized Patients With Heart Failure (OPTIMIZE-HF).25 
Among patients with left ventricular systolic   dysfunction 
(n = 3,001), beta-blockers were associated with adjusted HR of 
0.7 (95 CI: 0.68–0.87) for mortality, 0.89 (95% CI: 0.80–0.99) 
for rehospitalization, and 0.87 (95% CI: 0.79–0.96) for 
  mortality–rehospitalization. Patients with preserved systolic 
function had poor outcomes, and   beta-blockers did not signifi-
cantly influence the mortality and rehospitalization risks.
Nebivolol
Nebivolol is a lipophilic, third-generation, highly cardiose-
lective, beta1-adrenergic receptor antagonist characterized by 
endothelium nitric oxide (NO)-dependent vasodilation.26–28 
Unlike other third-generation beta-blockers, such as 
carvedilol and labetalol, which cause vasodilatation via 
alpha1-mediated receptor antagonism, nebivolol is unique 
in that it causes peripheral vasodilatation via L-arginine/
NO-induced release from endothelial cells and subsequent 
increased nitric oxide bioavailability in the endothelium.29–31 
In healthy subjects, brachial artery infusion of nebivolol 
significantly increases forearm blood flow, which is reduced 
by NC-monomethyl-L-arginine (L-NMMA), an inhibitor 
of NO synthase, and is restored by infusion of L-arginine.32 
These findings indicate that nebivolol vasodilatory activity 
is dependent on the L-arginine/NO pathway. NO is a major 
endothelium-derived vasodilatory compound that is also 
reported to have antithrombotic, antiproliferative, and anti-
inflammatory effects as well as lead to decreased myocardial 
oxygen demands.
Nebivolol is a racemic mixture of equal parts d- and 
l-nebivolol. The d-isomer is responsible for beta1-  adrenergic 
receptor antagonism, while the l-isomer is primarily 
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Figure 1 Der Simonian and Laird relative risks (random effects) plot of beta-blocker 
versus placebo in the subgroup of elderly patients with heart failure. Point estimates 
and 95% CIs represented next to box plot. 
Abbreviations: BEST, beta-blocker evaluation survival trial; CIBIS II, the cardiac 
insufficiency bisoprolol study II; COPERNICUS, carvedilol prospective randomized 
cumulative survival; MERIT-HF, metoprolol CR/XL randomized intervention trial in 
congestive heart failure. Copyright© 2005. Modified with permission from Elsevier. 
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  responsible for vasodilatation, with some contribution from 
the d-isomer. Nebivolol demonstrates beta1-receptor selec-
tivity that is 321-fold higher than for the beta2-receptor at 
doses less than or equal to 10 mg in extensive metabolizers, 
which is a majority of the population. Thus, it is the most 
cardioselective beta-blocker currently available. However, 
at daily doses .10 mg or in poor metabolizers, it is reported 
to lose this potent cardioselectivity. Nebivolol is devoid of 
membrane-stabilizing activity, intrinsic sympathomimetic 
activity, and alpha1 antagonist properties at therapeutic 
concentrations.33
Recent studies suggest that the endothelium-dependent 
vasodilation through activation of the NO pathway by 
nebivolol may be mediated via a beta3-adrenergic receptor 
agonist,34 and that in the myocardium this stimulation may 
induce a NO-dependent negative inotropic effect that poten-
tially could improve the energetic balance in the heart.35
Nebivolol lowers heart rate and blood pressure, and 
improves systolic and diastolic function. The hemodynamic 
profile of nebivolol is different from traditional beta-blockers 
in that it increases stroke volume while reducing peripheral 
vascular resistance and increasing left-ventricular ejection 
fraction. Nebivolol has a neutral effect on cardiac output and 
may increase exercise capacity.36–39 A significant improve-
ment in LVEF with nebivolol vs placebo was also seen in 
the study elderly heart failure patients in the efficacy of 
nebivolol in the treatment of elderly patients with chronic 
heart failure (ENECA) as add-on therapy to ACE inhibitors or 
angiotensin II receptor blockers, diuretics, and/or digitalis, and 
also in a small echocardiographic substudy of the study of the 
effects of nebivolol intervention on outcomes and rehospital-
ization in seniors with heart failure (SENIORS).40,41 In patients 
with hypertension, nebivolol, compared with atenolol, has been 
shown to improve diastolic function by means of a decrease in 
isovolumic relaxation time, deceleration time of the mitral flow 
velocity, and increase in the early and late (atrial) (E/A) ratio.42 
Unlike nonselective beta-blockers, which may cause airway 
obstruction due to antagonist activity at beta2-  adrenoceptors, 
nebivolol did not affect airway patency in patients with asthma 
or chronic obstructive pulmonary disease.43
In the SENIORS trial, changes in fasting serum glucose 
for nondiabetic patients were 0.54 mg/dL and 0.9 mg/dL for 
nebivolol and placebo, respectively. For diabetic patients, 
there were reductions in fasting serum glucose of 5.76 mg/dL 
and 1.98 mg/dL for nebivolol and placebo, respectively. 
Although not statistically significant, nebivolol was   associated 
with fewer cases of new onset diabetes mellitus than placebo 
(1.8% nebivolol vs 2.1% placebo).44
Caution and consideration for dose-adjustment of nebivolol 
is recommended for patients with severe renal impairment 
(creatinine clearance , 30 mL/min), as the apparent clearance 
of nebivolol was decreased by 53% in this patient population. 
Nebivolol should be used with caution in patients receiving 
dialysis, as no formal studies have been conducted in these 
patients. Nebivolol is also contraindicated in patients with 
severe hepatic impairment because of a lack of data in these 
patients.
Clinical aspects of nebivolol in older 
patients with heart failure
Comparative studies
One randomized, single-blinded, open-label, parallel-group, 
6-month study45 compared the effects of nebivolol vs carve-
dilol on left ventricular function in 70 patients in NYHA 
Class II or III and with LVEF # 40% (mean age 67-years-
old, mean LVEF 34%). Patients were randomized 1:1 to 
carvedilol 3.125 mg twice daily, titrated to target 25 mg twice 
daily if systolic blood pressure (SBP) . 110 mmHg and heart 
rate . 60 beats per minute (bpm), or nebivolol 1.25 mg daily 
titrated to target 5 mg daily if SBP . 110 mmHg and heart 
rate . 60 bpm. Carvedilol target dose was achieved in 77% 
of patients, while nebivolol target dose was achieved in 83% 
of patients. Compared with baseline, LVEF increased in both 
carvedilol arm (33% ± 6% to 37% ± 11%) and nebivolol arm 
(34% ± 7% to 38% ± 10%), with nonsignificant between-
group differences. NYHA Class improved slightly in both 
arms, although only the carvedilol arm reached statistical 
significance (P , 0.05). Adverse effects occurred in 20% of 
carvedilol and 26% of nebivolol recipients, with one patient 
drop-out in each treatment arm. The most common adverse 
effects in each arm were fatigue and dizziness.
Another randomized, prospective, double-blinded, 
parallel-group study compared the efficacy of nebivolol vs 
carvedilol on LVEF and exercise capacity in 72 heart fail-
ure patients with NYHA Classes II–III and non-ischemic 
dilated cardiomyopathy.46 After a titration phase to target 
doses of 5 mg daily of nebivolol and 25 mg twice daily of 
carvedilol, patients were followed for 12 months. LVEF 
was shown to significantly increase at 3 and 12 months from 
baseline in both nebivolol and carvedilol arms (P , 0.05). An 
intergroup-analysis revealed that carvedilol was associated 
with a greater effect on LVEF at 3 months (32.1% ± 34.9% 
vs 15.3% ± 15.9%, mean difference -16.7 ± 16.5, P = 0.04) 
and 12 months (35.5% ± 31.9% vs 20.7% ± 19.1%, mean 
difference -14.7 ± 6.4, P = 0.002) compared with nebivolol. 
Exercise duration significantly improved at 12 months in Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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both the nebivolol (P = 0.01) and carvedilol arm (P = 0.01), 
with no significant between-group differences. An initial 
deterioration in exercise capacity was seen after 3 months in 
nebivolol-treated patients but was not observed in carvedilol-
treated patients. Although nebivolol was likely under-dosed 
in these two studies, they are currently the only published 
prospective comparator trials and helped to pave the way for 
two larger-scale, placebo-controlled trials.
ENECA study
The ENECA study evaluated the effects of nebivolol vs 
placebo on ventricular remodeling as well as its safety 
and   tolerability, in elderly heart failure patients.40 In this 
randomized, prospective, multicenter, placebo-controlled, 
double-blinded, parallel-group study, 260 patients, aged 
more than 65-years-old (mean age 72-years-old) in NYHA 
Class II to IV and LVEF # 35%, were randomized to either 
nebivolol (mean dose 7.2 mg; 64.2% achieved target 10 mg 
daily) or placebo, as an add-on to usual therapy. The primary 
end-point of the study was the absolute change in LVEF 
in comparison with baseline value. Secondary end-points 
were total   mortality, change in NYHA Class,   hospitalization 
rates and quality of life, assessed with the Minnesota   Living 
with Heart Failure Questionnaire (MLHFQ). A total of 
124 and 112 patients in the nebivolol and placebo groups, 
respectively, completed the study. Improvement in LVEF 
was significantly greater in nebivolol-treated vs placebo-
treated patients (6.51% vs 3.97%; P = 0.027). A subgroup 
analysis revealed that nebivolol-treated males with no prior 
myocardial infarction history or with heart rate .75 bpm 
demonstrated the highest relative improvement in LVEF. In 
terms of NYHA Class changes, 33 patients in the nebivolol 
group improved by one class compared to 34 patients in the 
placebo group. The overall difference in functional status 
between the two groups was not statistically significant. 
Following 8 months of treatment, there was no difference 
in mean value of the total score of the MLHFQ between 
nebivolol and placebo (-9.1% ± 13.8% vs -11.0% ± 14.6% 
placebo; P = not   significant [ns]).
Nebivolol-treated patients (baseline: 76.9 ± 10.8 bpm vs 
8 month: 67.1 ± 9.2 bpm) had a significantly lower heart rate 
compared to placebo (baseline: 75.3 ± 9.9 bpm vs 8 month: 
75.0 ± 9.6 bpm, P , 0.0001). Nebivolol was well tolerated, 
as 64% of patients achieved the maximum dose of 10 mg, 
and the incidence of adverse events was no different from 
the placebo group. Bradycardia, hypotension, and   dizziness 
were the most frequent drug-related adverse effects in patients 
treated with nebivolol. The results of the ENECA study 
indicated that in elderly heart failure patients nebivolol is 
well tolerated and may significantly improve LVEF.
SENIORS study
The SENIORS study evaluated the safety, efficacy, and 
tolerability of nebivolol in the management of heart failure 
in the elderly. This was a randomized, prospective, multi-
national, multicenter, placebo-controlled, double-blinded, 
parallel-group study to evaluate the effects of nebivolol on 
mortality and hospitalization in clinically stable patients 
aged $ 70 years in NYHA Classes I–IV.47,48 The study 
enrolled 2128 patients with documented heart failure admis-
sion within the previous 12 months or documented LVEF 
less than 35% within the previous 6 months. Patients that 
were excluded from the study included those treated with 
beta-blocker therapy; patients with heart failure secondary 
to valvular disease; those that had severe coronary artery 
disease and had a revascularization procedure planned; 
  contraindications or previous intolerance to beta-blockers, 
or change in   cardiovascular therapy in the 2 weeks before 
randomization. The mean age of patients was 76-years-old, 
and most were in NYHA class II (56%) and III (39%). All 
patients underwent echocardiography after entry to the study, 
prior to administration of the study drug. LVEF was #35% in 
64% of subjects and .35% in 36%. Prior hypertension was 
present in 61%, coronary artery disease in 69% and previ-
ous myocardial infarction in 44% of patients. Patients were 
randomized to placebo (n = 1061) or nebivolol (n = 1067) 
at a starting dose of 1.25 mg once daily titrated to 10 mg 
once daily over a 4–16 week period, as tolerated. Patients 
were followed from 12 to 39 months (average follow-up 
21 months).
Treatment with nebivolol resulted in a statistically sig-
nificant 14% decrease in the primary composite endpoint 
(all-cause death or cardiovascular hospitalization) vs placebo. 
The primary endpoint occurred in 332 (31.1%) nebivolol-
treated patients vs 375 (35.3%) placebo-treated patients 
(HR = 0.86; 95% CI: 0.74–0.99; P = 0.039) (  Figure 2). 
The absolute risk reduction was 4.2%, suggesting a number 
needed to treat (NNT) of 24 patients for 21 months to avoid 
one event. The difference between nebivolol and placebo 
was evident after 6 months and gradually increased during 
the follow-up. The interaction between the primary outcome 
and some demographics [gender, age] and clinical factors 
[prior acute myocardial infarction, diabetes] was not statisti-
cally significant. The decrease in incidence of the primary 
end-point was similar in patients with reduced or preserved 
LVEF (Figure 3).Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Among secondary outcomes, the incidence of   cadiovascular 
mortality or cardiovascular hospitalization was also sig-
nificantly lower in patients treated with nebivolol than in 
those receiving placebo (28.6 vs 33.0%; HR 0.90; 95% CI: 
0.72–0.98; P = 0.02). By contrast, there were no significant 
between-group differences for the other secondary endpoints. 
In particular, all cause mortality was 15.8% in the nebivolol 
group and 18.1% in the placebo group (HR 0.88; 95% CI: 
0.71–1.08; P = ns). Results for functional assessment (NYHA 
mean class and the 6-minute walk test) have not yet been 
reported.48
The proportion of patients reaching a dose of nebiv-
olol greater than or equal to 5 and 10 mg at the end of the 
titration period was 80 and 68% of subjects, respectively 
(similar to the placebo group rates) and the mean maintenance 
dose was 7.7 mg per day. Nebivolol was generally well-
tolerated, as compared to other approved beta-blockers.18–20 
Premature discontinuation for any reason other than death 
occurred in 27% and 25% in the nebivolol and placebo 
groups,   respectively. There was an increased incidence of 
  bradycardia in   nebivolol-treated patients (11.1% vs 2.6% 
placebo). Bradycardia was the cause for study withdrawal in 
18 nebivolol-treated patients and four placebo-treated patients 
(no statistical analysis reported) (Figure 4). Hypotension 
incidence was similar in the nebivolol (7.7%) and placebo 
(7.2%) groups. In summary, the SENIORS study showed that 
nebivolol is well tolerated and effective in reducing mortality 
and morbidity in elderly patients with heart failure.
SENIORS substudies
A subgroup of SENIORS patients underwent complete 
echocardiographic recording in order to assess the effect of 
nebivolol treatment on systolic and diastolic ventricular func-
tion.41 The substudy randomized 112 patients in 29 European 
centers, of whom 104 were evaluable for the study; 43 had 
an ejection fraction (EF) # 35% and 61 had an EF . 35%. Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Left ventricular end-systolic volume, LVEF, mitral valve E/A 
ratio, and E-wave deceleration time were assessed at base-
line and after 12 months. Nebivolol   significantly increased 
LVEF (4.6%; P = 0.008) and decreased end-systolic vol-
ume (P = 0.016) in patients with systolic left ventricular 
  dysfunction (,35%), confirming the results of the ENECA. 
On the other hand, no significant changes were observed in left 
ventricular structure and function in patients with preserved 
or slightly reduced systolic function (EF . 35%).
In another prespecified substudy the effects of nebivolol 
in the subgroups with impaired EF (,35%) and preserved 
EF (. 35%) were explored. Forty-nine of the 2,111 patients, 
1,359 (64%) had impaired LVEF (mean 28.7%) and 752 
(36%) had preserved LVEF (mean 49.2%). The effect of 
nebivolol was investigated in these two groups, and it was 
compared to explore the interaction of LVEF with out-
come. Follow-up was 21 months; the primary end-point 
was all-cause mortality or cardiovascular hospitalizations. 
Patients with preserved LVEF were more often women 
(49.9% vs 29.8%) and had less advanced heart failure, 
more   hypertension, and fewer prior myocardial infarctions 
(all P , 0.001). During follow-up, the primary end-point 
occurred in 465 patients (34.2%) with impaired LVEF and 
in 235 patients (31.2%) with preserved LVEF. The effect 
of nebivolol on the   primary end-point HR of nebivolol vs 
placebo was 0.86 (95% CI: 0.72–1.04) in patients with 
impaired EF and 0.81 (95% CI: 0.63–1.04) in preserved 
LVEF (P = 0.720 for subgroup interaction). Effects on all 
secondary end-points were similar between groups (HR 
for all-cause mortality 0.84 and 0.91, respectively), and no 
P value for interaction was ,0.48. The authors concluded 
that the effect of beta-blockade with   nebivolol in elderly 
patients in this study was similar in those with preserved and 
impaired LVEF. However, it should be noted that although 
the primary outcome composite end-point was similar in 
low and preserved LVEF groups, there was only a 1.1% 
absolute (difference n = 3) reduction in all-cause mortal-
ity in those with LVEF . 35% versus a 2.8% (difference 
n = 20) absolute difference for those with LVEF # 35%.
More recently, a substudy of SENIORS evaluated 
the safety and efficacy of nebivolol in patients with renal 
dysfunction.50 Patients (n = 2112) were divided by tertile 
of estimated glomerular filtration rate (eGFR). The eGFR 
was strongly associated with outcomes and nebivolol was 
similarly efficacious across eGFR tertiles. The primary 
outcome rate (all-cause mortality or cardiovascular hospital 
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admission) and adjusted HR for nebivolol use in those with 
low eGFR was 40% and 0.84 (95% CI: 0.67–1.07), 31% 
and 0.79 (0.60–1.04) in the middle tertile, and 29% and 
0.86 (  0.65–1.14) in the highest eGFR tertile. There was 
no interaction between renal function and the treatment 
effect (P = 0.442). Nebivolol use in patients with   moderate 
renal impairment (eGFR , 60) was not associated with 
major safety   concerns, apart from higher rates of drug 
  discontinuation due to   bradycardia. The authors concluded 
that nebivolol is safe and has a similar effect in elderly 
patients with mild or moderate renal impairment.
SENIORS post-hoc analyses
Three post-hoc analyses have been carried out in subgroups of 
SENIORS patients. The all-cause mortality relative risk reduc-
tion of nebivolol vs placebo in SENIORS was 12% compared 
with risk reductions of 34%–35% for   bisoprolol, carvedilol and 
metoprolol CR/XL versus placebo in the cardiac insufficiency 
bisoprolol study- (CIBIS) II, carvedilol prospective randomized 
cumulative survival (  COPERNICUS), and metoprolol CR/XL 
randomized intervention trial in congestive heart failure (MER-
IT-HF) trials.18–20 In order to compare the SENIORS results to 
those of the other   trials, the authors of SENIORS conducted a 
not prespecified exploratory analysis in one subgroup that more 
closely resembled patient groups from the other beta-blocker 
trials.47 In the subgroup of nebivolol patients aged ,75.2-years-
old who had an LVEF # 35%, the risk reduction for all-cause 
  mortality was 38% (Figures 5 and 6).
A second post-hoc analysis assessed the tolerability and 
dose-related effects of nebivolol.51 Patients assigned to nebiv-
olol (n = 1031) were classified into 4 groups, according to the 
dose achieved at the end of titration phase (maintenance dose): 
0 mg (n = 74), low dose (1.25 or 2.5 mg, n = 142), medium 
dose (5 mg, n = 127), and target dose (10 mg, n = 688) and 
compared with those allocated to placebo (n = 1030). Age, 
sex and LVEF were similar between the groups, but prior 
myocardial infarction, coronary revascularization, and serum 
creatinine levels were lower in patients who achieved higher 
maintenance doses of nebivolol. After adjustment, all-cause 
mortality or cardiovascular hospitalization was significantly 
reduced in the 10 mg dose group compared with placebo (HR 
0.75, 95% CI: 0.63–0.90) which was similar to the medium 
dose group (HR 0.73, 95% CI: 0.52–1.02). The low dose group 
had an apparently lower benefit (HR 0.88, 95% CI: 0.64–1.20), 
whereas patients unable to tolerate any dose of nebivolol had 
an increased risk of death or cardiovascular hospitalization 
(HR 1.95, 95% CI: 1.38–2.75) (Figure 7). The authors con-
cluded that the benefits of nebivolol in elderly patients with 
heart failure appear to be related to the maintenance dose 
achieved. Patients unable to tolerate any dose have the worst 
prognosis. However, the reasons for 32% of patients not reach-
ing the 10 mg daily dosage were not reported.
Another post-hoc analysis for the endpoint of sudden 
cardiac death reported an HR of 0.62 for nebivolol versus pla-
cebo (95% CI: 0.42, 0.91; P = 0.014). These nonprespecified 
analyses should be considered exploratory and hypothesis-
generating and may suggest possible areas for future   
research.52
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Economic aspects of nebivolol therapy
In the SENIORS trial the cost-effectiveness of nebivolol 
compared with standard medical therapy was evaluated 
using a Markov Monte Carlo simulation model developed 
to assess the cost, survival, quality adjusted survival and 
cost effectiveness of nebivolol over the patient’s life time.53 
Health states were defined as stable condition, cardiovascular 
hospitalization events, death in hospital, sudden death, and 
death due to other causes, based on monthly cycles. Patients’ 
characteristics, time to sudden death, time to   hospitalization 
with standard medical therapy, the hazard ratios with 
  nebivolol, and resource used data were derived from the 
SENIORS clinical trial. Utility scores for each NYHA class 
were derived from a large heart failure trial. The economic 
analysis was conducted from the UK health care perspective 
including costs of hospitalization, drug cost, cost of treatment 
for severe adverse effects and general practitioner visit cost. 
A fully probabilistic sensitivity analysis for all input values 
to explore uncertainty derived from the model parameters 
was conducted. Costs and outcomes were discounted at 
3.5% annually. The model predicted that the total cost per 
patient for the nebivolol group was $18,120 compared with 
$14,298 for standard medical treatment respectively. The 
mean life-years were 8.49 and 7.16 and quality-adjusted 
life years (QALYs) were 5.69 and 4.80 for nebivolol and 
medical standard treatment respectively. The probabilistic 
sensitivity analysis gave an incremental cost of $3,822, a 
QALYs score of 0.88 and a life year estimate of 1.32. This 
gives incremental cost-  effectiveness ratios (ICERs) of $4,322 
(95% CI: $3,975–$4,731) per QALY gained and $2,888 (95% 
CI: $2,663–$3,170) per life year gained. This model-based 
analysis indicates that nebivolol is highly cost-effective, 
achieving an incremental cost-effectiveness ratio well below a 
standard benchmark used for resource allocation decisions in 
elderly people with heart failure, when compared to   standard 
medical therapy.
Discussion
Subgroup analyses,21,22 meta-analyses23 and observational 
studies24,25 showed a beneficial effect of beta-blockers in 
elderly populations, including those with depressed and 
preserved LVEF. Approximately two-thirds of elderly 
patients with heart failure tolerate a beta-blocker, but only 
40%–70% of the target doses recommended in randomized 
trials are achieved. Moreover, the effect of beta-blockers on 
all-cause mortality may be lower in very elderly and frail 
patients.23 In other words, the level of evidence regarding 
beta-blocker therapy in the elderly is not regarded as high 
as that in younger patients.
There is also evidence that beta-blockers are less fre-
quently prescribed in elderly patients in clinical practice, 
and that this lack of treatment is associated with impaired 
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outcomes. Establishing which beta-blockers are effective in 
the elderly is therefore of importance. The elderly have a 
reduced cardiovascular reserve and may be less tolerant to a 
vasoconstricting beta-adrenoceptor antagonist. In addition, 
the higher proportion of elderly heart failure patients with rela-
tively preserved systolic function (for which no   treatment has 
been proven to reduce mortality and morbidity) and with mul-
tiple comorbidities and age-related impairments means that we 
cannot say with certainty that beta-blockers have been proven 
to be effective in a general elderly heart failure population.
Third-generation beta-adrenoceptor antagonists with 
vasodilating properties may offer several theoretical 
advantages. Three of this class (carvedilol, bucindolol and 
nebivolol) have been evaluated in heart failure, and only two 
of these (carvedilol and nebivolol) had a proven outcome 
benefit in a properly powered randomized, controlled trial. 
In SENIORS, nebivolol was more effective than placebo 
in reducing the risk of the composite endpoint of all-cause 
mortality or cardiovascular hospitalization and was gener-
ally well tolerated in elderly patients with heart failure with 
reduced or preserved systolic function.47
Despite the beneficial results of SENIORS, some uncer-
tainty or disagreement about whether beta-blockers are 
equally beneficial and well tolerated in elderly heart failure 
patients as in younger ones still remain. First, the HR for 
the primary outcome in the SENIORS was 0.86,47 a lesser 
risk reduction compared with previous large beta-blocker 
trials.18–20 As suggested, there are several possible reasons 
for this:27,54,55 1) nebivolol, at the dose used in the trial, might 
be inferior to the other beta-blockers tested; 2) the marked 
differences in populations enrolled (older and with less 
compromised left ventricular systolic function) and/or the 
different duration of follow-up in SENIORS compared with 
other beta-blocker trials in heart failure might account for the 
differences in outcomes; and 3) older patients may respond 
differently to drugs in terms of efficacy and tolerability.
Older patients enrolled in SENIORS may not fully 
reflect the clinical profile of the “real world” elderly. Indeed, 
SENIORS enrolled patients selected for low comorbidities 
(and age-related impairments) and probably at low-risk of 
mortality and morbidity. The event rate in SENIORS was 
unexpectedly low, because all cause mortality at a mean 
follow-up of 21 months in the placebo group (18.1%) 
was significantly lower than that previously reported. For 
example, in the observational study beta-blockers in patients 
with congestive heart failure: guided use in clinical practice 
(BRING-UP), patients older than 70 years enrolled in cardi-
ology heart failure clinics and not treated with beta-blockers 
had the same mortality rate (18%) at 12 months.56 If we 
consider unselected community-living older patients with 
multiple comorbidities and age-related impairments enrolled 
at discharge from hospital in a disease management program, 
the 24-month all-cause mortality rises up to 34.1% (18.3% 
in patients tolerating and 52.5% in those not tolerating beta-
blockers).57
Although SENIORS demonstrated a clear benefit of 
nebivolol, it is not possible to directly compare outcomes 
between SENIORS and other beta-blockers trials because 
of the differences in trial design.48 The benefit of nebivolol 
on mortality in older adults may be attenuated by competing 
contributors to death not modifiable by nebivolol. More-
over, although the prespecified component of the primary 
end-point, that is, cardiovascular hospitalization, was reduced 
by nebivolol, all-cause hospitalization was unchanged.
Other trials included younger patients (and excluded very 
old patients) with low LVEF (#40%) and used   different study 
endpoints.18–20 The authors of SENIORS therefore conducted 
exploratory analyses (not prespecified) in subgroups that more 
closely resembled patient groups from other studies.52 The 
risk reduction for all-cause mortality (the primary endpoint in 
CIBIS-II and COPERNICUS and one of the primary endpoints 
in MERIT-HF) for nebivolol compared with placebo was 12% 
in SENIORS compared with risk reductions of 34%–35% 
for bisoprolol, carvedilol and metoprolol CR/XL versus pla-
cebo. However, in the subgroup of nebivolol recipients from 
SENIORS aged , 75.2 years who had an LVEF # 35%, the 
risk reduction for all-cause mortality was 38% (Figure 6).
When analyzed according to age strata, the oldest patients 
(above the median age of 75.2 years) derived somewhat a less 
benefit (not statistically significant) than younger patients. It may 
be argued that the increased risk of death from other causes in 
the elderly may compete with the potential benefits of treatment. 
Thus, it is plausible that there is a threshold of biological age, 
beyond which the benefit of any treatment is difficult to demon-
strate. Although the benefits of nebivolol appeared to be reduced 
in patients aged greater than 75 years, age as a continuous vari-
able did not significantly affect the treatment effect.47,54,55
The results of SENIORS also extend the benefit of 
beta-blocker therapy to patients with preserved left ven-
tricular systolic function, a sizable proportion of heart 
failure patients. However, these patients represented only 
a third of the patients enrolled in the SENIORS trial, and 
the LVEF cut-off was 35%, far different from that of 
45%–50% usually considered in epidemiological studies 
as “preserved” LVEF. Indeed, the exact percentage of 
patients with normal LVEF (ie, .50%) was not reported Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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in the study47 and that of patients with LVEF . 40% was 
30.4%.49 Therefore, this is just a hypothesis that requires 
confirmation in properly designed and powered studies. 
Theoretically, there are several reasons why nebivolol 
might improve diastolic function. The decrease in heart 
rate by prolonging the diastolic filling time more than the 
ejection time should improve myocardial perfusion and 
metabolism. The increased NO release caused by nebivolol 
might also improve early relaxation. Previously, a small 
echocardiographic substudy of the SENIORS trial failed 
to show any improvement in diastolic performance.41 
However, in the long term of a progressive condition such 
as heart failure, the subtle changes in diastolic function 
might not be captured by a technique sensitive to multiple 
factors, including the loading conditions, such as standard 
Doppler echocardiography. The question of whether or not 
nebivolol can improve left ventricular diastolic function 
remains unanswered.55
With respect to the dose achieved in the SENIORS trial, 
only the highest doses of nebivolol were associated with a 
significant event reduction. During the titration phase, 7% 
of patients could not tolerate any nebivolol, and 33% were 
not at the dose at which mortality benefit was clear.47,51 
  Post-hoc analyses from SENIORS suggesting that nebivolol 
may reduce sudden cardiac death and that greater benefits 
are achieved in those who reach the target maintenance dose 
of 10 mg/day require further investigation. Patients unable 
to tolerate target doses were older and were more likely to 
be receiving other medications that alter heart rate and con-
duction (antiarrhythmic agents and calcium blockers). This 
underscores the challenges of the generalizability of this 
trial to older adults in clinical practice, where polypharmacy, 
pre-existing frailty, and conditions affecting tolerability of 
beta-blockers in maximal doses are more prevalent. Thus, the 
open question is whether we should use the same target dose 
in the elderly as that in younger patients. Theoretically, the 
most effective dose is the highest dose tolerated, which may 
differ across different age groups and may not be applicable 
to the frail, older population. In these complex and vulnerable 
patients it is therefore time to shift from the paradigm of the 
“target dose” to that of the “highest dose tolerated”.55 On 
the other hand, data from observational studies suggest that 
“low dose” is better than “no dose”, because the prognosis 
of patients intolerant to beta-blockers is worse.24,25
Finally, the prespecified secondary outcomes of functional 
capacity by NYHA functional class and 6-min walk test in the 
SENIORS trial have never been reported: these data would 
greatly assist clinicians in applying the overall result.48
In summary, SENIORS is the first and only trial that has 
prospectively investigated beta-blocker treatment of heart fail-
ure elderly patients, including those with relatively preserved 
systolic function, and demonstrated a significant reduction 
in the risk of death or cardiovascular hospitalization. Thus, 
nebivolol should be considered as an alternative first-line 
treatment option in selected elderly patients with heart failure. 
Moreover nebivolol appears to be significantly cost-effective 
when prescribed in these patients. However, in order to better 
define the profile of efficacy and safety of beta-blockers in 
older patients, further data are needed from targeted clinical 
trials and rigorous observational studies, showing definite 
improvement in outcomes as well as clearly favorable benefit-
risk analysis in typical older heart failure patients irrespective 
of comorbidity, frailty and polypharmacy.
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